News

B.C. funds new cancer treatment test

By The Canadian Press

VANCOUVER - B.C. has become the latest province to fund a test that can help determine whether patients with a certain type of early stage breast cancer could benefit from chemotherapy.

California-based Genomic Health says the BC Cancer Agency has agreed to fund the company's Oncotype DX test.

The test, which costs US$4,300, examines genes within breast cancer tumours to predict which patients would benefit from chemotherapy.

Conversely, the test is also used to predict which patients would see little or no benefit from chemotherapy.

The funding applies to patients that meet a list of criteria, including that they have early stage, node-negative, estrogen receptor-positive invasive breast cancer.

The test is already funded by provincial governments in Alberta, Ontario, Quebec, Saskatchewan, and Newfoundland and Labrador.

We encourage an open exchange of ideas on this story's topic, but we ask you to follow our guidelines for respecting community standards. Personal attacks, inappropriate language, and off-topic comments may be removed, and comment privileges revoked, per our Terms of Use. Please see our FAQ if you have questions or concerns about using Facebook to comment.

You might like ...

Court challenge aims to block new coal terminal
 
Jet fuel pipeline plan put on hold
 
Gun amnesty yielded 1,800 firearms in B.C.
Roost draws mixed reviews
 
Photos show gruesome Islamic State seizure of base
 
Rasode declares run for Surrey mayor
Surrey woman shot in front of her son
 
Busload of high school grads involved in Cloverdale brawl
 
Coroner probes B.C. youth suicides

Community Events, September 2014

Add an Event

Read the latest eEdition

Browse the print edition page by page, including stories and ads.

Sep 19 edition online now. Browse the archives.